The estimated Net Worth of Jennifer G Clasby is at least $472 Mille dollars as of 17 June 2021. Ms. Clasby owns over 24,510 units of Eyenovia Inc stock worth over $44,919 and over the last 6 years she sold EYEN stock worth over $0. In addition, she makes $426,637 as Vice President - Clinical Operations at Eyenovia Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Clasby EYEN stock SEC Form 4 insiders trading
Jennifer has made over 3 trades of the Eyenovia Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently she exercised 24,510 units of EYEN stock worth $47,795 on 17 June 2021.
The largest trade she's ever made was exercising 28,965 units of Eyenovia Inc stock on 10 September 2018 worth over $56,482. On average, Jennifer trades about 11,459 units every 144 days since 2018. As of 17 June 2021 she still owns at least 80,212 units of Eyenovia Inc stock.
You can see the complete history of Ms. Clasby stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jennifer Clasby biography
Jennifer Clasby serves as Vice President - Clinical Operations of the Company. From 2009 to September 2017, she served as Vice President, Clinical & Regulatory Affairs/Quality Assurance at Transcend Medical, Inc. In that position, she was responsible for overseeing clinical operations and regulatory processes for the company’s clinical trials in the United States, Europe and Latin America, as well as worldwide regulatory affairs, quality assurance and compliance activities. She was also a pivotal executive with Promedica International, a contract research organization, from 1994 to 2009. Prior to that, Clasby worked with ophthalmic device companies American Medical Optics, Inc. (currently known as Johnson & Johnson Vision Care, Inc.) and Optical Radiation Corporation (now part of EssilorLuxottica (Euronext Paris: EL)) in various roles for approximately 14 years in the areas of clinical affairs, manufacturing operations, marketing and sales. She serves on the University of California-Irvine Extension Life Science Advisory Committee. She holds an M.S. degree in Industrial Engineering from Arizona State University and B.S. degrees in mathematics and physics from Guilford College.
What is the salary of Jennifer Clasby?
As the Vice President - Clinical Operations of Eyenovia Inc, the total compensation of Jennifer Clasby at Eyenovia Inc is $426,637. There are 5 executives at Eyenovia Inc getting paid more, with Tsontcho Ianchulev having the highest compensation of $1,247,140.
How old is Jennifer Clasby?
Jennifer Clasby is 66, she's been the Vice President - Clinical Operations of Eyenovia Inc since 2017. There are 3 older and 9 younger executives at Eyenovia Inc. The oldest executive at Eyenovia Inc is Ernest Mario, 81, who is the Independent Director.
What's Jennifer Clasby's mailing address?
Jennifer's mailing address filed with the SEC is C/O EYENOVIA, INC., 295 MADISON AVENUE, SUITE 2400, NEW YORK, NY, 10017.
Insiders trading at Eyenovia Inc
Over the last 7 years, insiders at Eyenovia Inc have traded over $1,275,000 worth of Eyenovia Inc stock and bought 6,072,235 units worth $17,599,075 . The most active insiders traders include Ernest Mario, Stuart M. Grant e Fredric N Eshelman. On average, Eyenovia Inc executives and independent directors trade stock every 31 days with the average trade being worth of $49,678. The most recent stock trade was executed by Michael M Rowe on 28 August 2024, trading 27,071 units of EYEN stock currently worth $14,077.
What does Eyenovia Inc do?
eyenovia, inc. (nasdaq: eyen) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases.
What does Eyenovia Inc's logo look like?
Complete history of Ms. Clasby stock trades at Eyenovia Inc
Eyenovia Inc executives and stock owners
Eyenovia Inc executives and other stock owners filed with the SEC include:
-
Tsontcho Ianchulev,
Chief Executive Officer, Director, Chief Medical Officer -
Dr. Tsontcho Ianchulev M.P.H., M.D., MPH,
CEO, Pres, Chief Medical Officer & Director -
John Gandolfo,
Chief Financial Officer, Secretary -
John P. Gandolfo CPA,
CFO & Sec. -
Michael Rowe,
Vice President - Commercial -
Jennifer Clasby,
Vice President - Clinical Operations -
Michael M. Rowe,
Chief Operating Officer -
Fredric Eshelman,
Independent Chairman of the Board -
Tram Bui,
IR Contact Officer -
Anthony Sun,
Independent Director -
Charles Mather,
Independent Director -
Ernest Mario,
Independent Director -
Kenneth Lee,
Independent Director -
Curt Labelle,
Director -
Luke Clauson,
Vice President - Research &Development and Manufacturing -
Norbert Lowe,
VP of Sales & Marketing -
Alexander Lobo,
Investor Contact -
Andrew D. Jones,
Chief Financial Officer -
Julia A Haller,
-
Bren Kern,
Chief Operating Officer -
Pharmaceutical Co., Ltd. Senju,
10% owner -
Shuhei Yoshida,
Director -
Stuart M. Grant,
-
Stephen Keith Benjamin,
-
Rachel Jacobson,
Director -
Ellen R Strahlman,
Director -
Michael S Geltzeiler,
Director -
Ram Palanki,
Director